![](/images/graphics-bg.png)
Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature
المؤلفون المشاركون
Delacruz, Wilfred
Setlik, Robert
Hassantoufighi, Arash
Daya, Shyam
Cooper, Susannah
Selby, Dale
Brown, Alexander
المصدر
Case Reports in Oncological Medicine
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-10-11
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies which typically respond to standard first-line chemoimmunotherapy regimens.
Unfortunately, patients with refractory NHL face a poor prognosis and represent an unmet need for improved therapeutics.
We present two cases of refractory CD30+ NHL who responded to novel brentuximab vedotin- (BV-) based regimens.
The first is a patient with stage IV anaplastic large cell lymphoma (ALCL) with cranial nerve involvement who failed front-line treatment with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) and second line cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate (MTX), and cytarabine (hyperCVAD) with intrathecal- (IT-) MTX and IT-cytarabine, but responded when BV was substituted for vincristine (hyperCBAD).
The second patient was a man with stage IV diffuse large B-cell lymphoma (DLBCL) with leptomeningeal involvement whose disease progressed during first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and progressed despite salvage therapy with rituximab, dexamethasone, cytarabine, and cisplatin (R-DHAP) in whom addition of BV to topotecan resulted in a significant response.
This report describes the first successful salvage treatments of highly aggressive, double refractory CD30+ NHL using two unreported BV-based chemoimmunotherapy regimens.
Both regimens appear effective and have manageable toxicities.
Further clinical trials assessing novel BV combinations are warranted.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Delacruz, Wilfred& Setlik, Robert& Hassantoufighi, Arash& Daya, Shyam& Cooper, Susannah& Selby, Dale…[et al.]. 2016. Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature. Case Reports in Oncological Medicine،Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1101662
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Delacruz, Wilfred…[et al.]. Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature. Case Reports in Oncological Medicine No. 2016 (2016), pp.1-7.
https://search.emarefa.net/detail/BIM-1101662
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Delacruz, Wilfred& Setlik, Robert& Hassantoufighi, Arash& Daya, Shyam& Cooper, Susannah& Selby, Dale…[et al.]. Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature. Case Reports in Oncological Medicine. 2016. Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1101662
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1101662
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)